Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells

Kirk Jensen¹, Athanasios Bikas², Aneeta Patel¹, Yevgeniya Kushchayeva³, John Costello¹, Dennis McDaniel⁴, Kenneth Burman⁵ and Vasyl Vasko¹

¹Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
²Department of Internal Medicine, Georgetown University Hospital MedStar, Washington Hospital Center Internal Medicine Residency Program, Washington, District of Columbia, USA
³National Institutes of Health, NIDDK, Bethesda, Maryland, USA
⁴Uniformed Services University of the Health Sciences, Biomedical Instrumentation Center, Bethesda, Maryland, USA
⁵MedStar Washington Hospital Center, Endocrinology, Washington, District of Columbia, USA

Abstract

The HIV protease inhibitor Nelfinavir (NFV) inhibits PI3K/AKT and MAPK/ERK signaling pathways, emerging targets in thyroid cancers. We examined the effects of NFV on cancer cells that derived from follicular (FTC), papillary (PTC) and anaplastic (ATC) thyroid cancers. NFV (1–20 µM) was tested in FTC133, BCPAP and SW1736 cell lines. The effects of NFV on cell proliferation were determined in vitro using real-time microscopy and by flow cytometry. DNA damage, apoptotic cell death and expression of molecular markers of epithelial–mesenchymal transition (EMT) were determined by Western blot and real-time PCR. Real-time imaging demonstrated that NFV (10 µM) increased the time required for the cell passage through the phases of cell cycle and induced DNA fragmentation. Growth inhibitory effects of NFV were associated with the accumulation of cells in G0/G1 phase, downregulation of cyclin D1 and cyclin-dependent kinase 4 (CDK4). NFV also induced the expression of γH2AX and p53BP1 indicating DNA damage. Treatment with NFV (20 µM) resulted in caspase-3 cleavage in all examined cells. NFV (20 µM) decreased the levels of total and p-AKT in PTEN-deficient FTC133 cells. NFV had no significant effects on total ERK and p-ERK in BRAF-positive BCPAP and SW1736 cells. NFV had no effects on the expression of EMT markers (Twist, Vimentin, E- and N-Cadherin), but inhibited the migration and decreased the abilities of thyroid cancer cells to survive in non-adherent conditions. We conclude that NFV inhibits proliferation and induces DNA damage in thyroid cancer cell lines. Our in vitro data suggest that NFV has a potential to become a new thyroid cancer therapeutic agent.
Introduction

Thyroid cancer is the most common endocrine malignancy (Hundahl et al. 1998) and is also increasing at the fastest incidence rate of any malignancy (Morris et al. 2016). Patients with differentiated thyroid cancer have an excellent prognosis (Sherman 2003, Cabanillas et al. 2016); however, when thyroid cancer patients present with distant metastases at the time of surgery, the overall 10-year survival rate is only 40% (Muresan et al. 2008). Analysis of clinicopathologic features predictive of disease-specific mortality revealed that, in addition to distant metastases, gross tumor extension beyond the thyroid and poorly differentiated histology are closely linked to deaths in non-anaplastic follicular cell-derived thyroid carcinomas (Xu et al. 2016). Both recurrences and death from PTC can occur more than 30 years after being treated, and development of recurrent disease significantly worsens prognosis (Grogan et al. 2013). In patients stratified according to American Thyroid Association risk categories (low, intermediate or high), persistent structural disease or recurrence was identified in 3% of the low-risk, 21% of the intermediate-risk and 68% of the high-risk patients (Tuttle et al. 2010). The mortality of patients with a recurrence has been shown as high as 38–69% (Samaan et al. 1983, Tubiana et al. 1985). Loss of differentiation is generally associated with a poor prognosis, and patients with 131I-positive metastases have demonstrated a 60% 10-year survival in comparison with 10% for patients with 131I-negative metastases (Durante et al. 2006). Anaplastic thyroid cancer (ATC) is a rare form of thyroid cancer, but is associated with a poor prognosis because of rapid tumor growth and poor response to conventional treatments (Cabanillas et al. 2016).

Thus, patients with metastatic and recurrent thyroid cancers, as well as tumors that lose the ability to trap 131I, are obvious candidates for alternative therapeutic approaches.

Potential strategies for targeted therapy of thyroid cancer include inhibition of angiogenesis, inhibition of aberrant intracellular signaling in the MAPK and PI3K/AKT/mTOR pathways, radio-immunotherapy and re-differentiation agents (Liebner & Shah 2011). In addition, repositioning of well-established FDA-approved drugs for the treatment of cancer emerged as an alternative drug development strategy (Zhang et al. 2012, Kluborgwiedzinska et al. 2013, Kushchayeva et al. 2014b). For example, metformin, a well-known medication for the management of diabetes, demonstrated inhibitory effects on cancer cell growth in various experimental models of cancers. The retrospective analysis of clinicopathological characteristics in diabetic patients with thyroid cancer showed that tumor size was significantly smaller in metformin-treated compared to the non-metformin-treated groups. A multivariate model revealed that treatment with metformin increased the likelihood of a complete response and increased progression-free survival in thyroid cancer patients with diabetes (Kluborgwiedzinska et al. 2013). Several other medications are currently under investigation for their repositioning in the treatment of cancer patients.

Nelfinavir (NFV) is an HIV protease inhibitor that is currently being repositioned for cancer therapy. It is being evaluated in oncologic clinical trials for pancreatic cancer, non-small-cell lung cancer, liposarcoma and glioblastoma multiforme (Brunner et al. 2008, Pan et al. 2012, Rengan et al. 2012, Hill et al. 2016). Clinical observations have demonstrated that the toxicities associated with HIV protease inhibitors are similar to those observed with inhibition of the phosphoinositide 3-kinase (PI3K)/AKT pathway, a major anti-apoptotic signaling cascade in cancer. Subsequent experimental in vitro and in vivo studies demonstrated the inhibitory effects of NFV on PI3K/AKT signaling pathway in a variety of human cancers (Pore et al. 2006, Yang et al. 2006, Gills et al. 2007, Shim et al. 2012).

We have reported previously that NFV inhibited the viability of medullary thyroid cancer cells, decreased the level of RET protein and blocked the activation of RET downstream targets (phosphorylated ERK, phosphorylated AKT and p70S6K/pS6) (Kushchayeva et al. 2014b). These findings suggested that NFV could be effective against differentiated thyroid cancer cells with mutations in the PI3K/AKT pathway, as well as in tumors with activating mutations in MAPK–BRAF–ERK signaling.

In this study, we used thyroid cancer cells with different mutations and examined their response to treatment with NFV using real-time microscopy. We determined the effects of NFV on thyroid cancer cell growth, activation of thyroid oncogene-inducible signaling pathways, DNA damage and apoptosis. We also examined the effects of NFV on the migration of thyroid cancer cells in vitro.

Materials and methods

Thyroid cancer cells culture and reagents

Human thyroid cancer cell lines derived from follicular (FTC133), papillary (BCPAP) and anaplastic (SW1736)
thyroid cancers were obtained from Dr Motoyasu Saji (The Ohio State University) with permission from the researchers who originally established the cell lines. All cell lines had been tested and authenticated by DNA analysis to be of thyroid origin (Schweppe et al. 2008). These cell lines express common thyroid oncogenes including BRAF V600E (BCPAP and SW1736) or have loss of PTEN expression (FTC133). In our laboratory, we confirmed the mutation status of BCPAP and examined the expression of PTEN by Western blot in FTC133 cells.

Cancer cells were propagated in conventional RPMI-1640 medium (Invitrogen) supplemented with 10% of fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin in a humidified 5% CO2 incubator. The cells were subcultured with 0.5% trypsin and 0.02% EDTA (Sigma–Aldrich) when the cell confluency reached 80%. All experiments were performed using thyroid cancer cell lines that had been passaged fewer than 25 times.

The HIV protease inhibitor Nelfinavir was obtained from Sigma–Aldrich. Nelfinavir (NFV) was dissolved in dimethyl sulfoxide (DMSO) and kept as a stock solution at a concentration of 5 mM.

**Live cell imaging and cell viability assays**

For real-time microscopy, thyroid cancer cells were grown on eight-well Lab-Tek chamber slides at 50–60% confluency and treated with NFV (10 µM) for 24 h. Live cell imaging was performed using the Leica AF6000 Time Lapse Imaging System. Images were taken every 5 min. Sequential images were compiled into a time lapse video format.

Cell proliferation rate was determined by cell counting using the Vi-CELL Cell Viability Analyzer from Beckman Coulter (Fullerton, CA, USA), and cell viability was determined by Alamar blue assay. Dead cells were detected using propidium iodine staining. All experiments were repeated at least three times, and the average values of representative experiments are reported.

**Flow cytometry**

Flow cytometry analysis of cells stained with propidium iodide (PI) was performed on a BD LSRII flow cytometer. A 488 nm laser was used for the dye excitation; 595 long pass and 610/20 band pass filters were used for emission detection. Single cells were gated using forward scatter height and area parameters. The single cell population gate was confirmed by using area and width parameters of PI channel. The calculation of different phases of cell cycle was done using ModFit LT analysis software.

**Cell migration and anoikis assays**

Cell migration was examined by using a Boyden chamber (8-µm pore size), and cells were stained by using a Diff-Quick staining kit (Dade Behring, Newark, DE, USA). All migration experiments were performed on at least three occasions in duplicate.

For anoikis experiments, cells were cultured in low-adherent cell culture conditions (poly-HEMA-treated plates). In low-adherent conditions, cell viability was determined by the evaluation of mitochondrial membrane potential with a fluorogenic lipophilic cation (JC-1; Cayman Chemical Company).

**RNA extraction and quantitative RT-PCR**

Total RNA was isolated from thyroid cancer cells using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. SYBR green-based qPCR master mixtures were obtained from Qiagen. Quantitative RT-PCR screening of thyroid-specific genes (NKKX2-1, SLC5A5 (sodium iodide symporter) and TG (thyroglobulin)) as well as genes with an established role in the regulation of epithelial-to-mesenchymal transition (TWIST1, VIM (vimentin), CDH1 (E-Cadherin), CDH2 (N-Cadherin)) was performed using commercially available primers and probes from Qiagen.

**Protein extraction and Western blot analysis**

Thyroid cancer cells were incubated with ice-cold cell lysis buffer, scraped, centrifuged and the supernatant was stored at −80°C. Twenty-five micrograms of total protein lysate were suspended in reduced SDS sample buffer, and the lysates were subjected to SDS–PAGE (4–12%). The separated proteins were transferred to a nitrocellulose membrane (Invitrogen) by electrophoretic blotting. Membranes were incubated overnight with primary antibody against BRAF V600 (Spring Bioscience Corporation, Pleasanton, CA, USA); vimentin and b-actin (Sigma–Aldrich), p-AKT1/2/3 (Ser473), total AKT, p-ERK1/2, total ERK, retinoblastoma tumor suppressor protein (Rb), p-Rb, CDK4, cleaved caspase 3 and cleaved PARP (Cell Signaling Technology); N-Cadherin, Connexin-43, Cyclin D1, ɣH2AX and p53BP1 (Santa Cruz Biotechnology). Detection of proteins was performed using the Li-Cor Odyssey imaging system (LI-COR Biosciences, Lincoln, NE, USA).
Immunostaining

For immunostaining, thyroid cancer cells were cultured overnight on eight-chambered SuperCell Culture Slides (Thermo Fisher Scientific) and then fixed in formalin for 15 min. After washing with PBS, cells were incubated for 1 h at room temperature with anti-p53BP1 or anti-γH2AX antibody. Slides were then incubated at room temperature for 1 h with species-specific Alexa 488-conjugated secondary antibody.

Results

Assessment of thyroid cancer cells’ response to Nelfinavir by real-time microscopy

To determine the morphological changes in thyroid cancer during exposure to NFV (10 µM), we performed real-time microscopy for 24 h. Non-treated thyroid cancer cells were characterized by constant motion (Supplementary Videos 1, 2 and 3; see section on supplementary data given at the end of this article). Collective cell migration and single cell movements were observed in FTC133, SW1736 as well as in BCPAP cells. Cell count at 6, 12, 18 and 24 h showed that the number of cells almost doubled at 24 h in all examined cell lines. Live imaging revealed distinct morphological changes in cells undergoing division. These changes included cell–substrate adhesion remodeling (~15 min), resulting in cell rounding (~15 min), cellular elongation with formation of the central furrow (~30 min), the separation of two daughter cells (~15 min) and re-establishing adherence to substrate (~45 min). Representative images of the phases of BCPAP single cell division are presented in Fig. 1A. In FTC133, SW1736 and BCPAP, the entire process of cell division occurred within 120 ± 15, 145 ± 20 and 100 ± 25 min, respectively.

Treatment with NFV was associated initially with the inhibition of cell growth. As an example, in BCPAP cells, the time required for cell–substrate adhesion...
remodeling, cell rounding, formation of the central furrow, the separation of two daughter cells and re-adhesion was 30, 30, 90, 15 and 60 min, respectively (Fig. 1B). The time for the entire process of cell division was twice longer in NFV-treated BCPAP cells as compared to that in control cells. These effects of NFV were also observed in FTC133 and SW1736 cells. Dynamic imaging revealed that NFV affected the time required for cells to passage through the phases of cell cycle in all examined cell lines (Supplementary Videos 4, 5 and 6).

With extended exposure to NFV, thyroid cancer cells progressively lose their ability to form the central furrow and exhibited morphological features suggesting mitotic arrest (round, non-dividing cells for up to 4 h). NFV-treated cells were not able to proceed with mitotic exit and underwent apoptosis (Fig. 1C and Supplementary Videos 4, 5 and 6).

To confirm these observations, we assessed the viability of thyroid cancer cells by performing Alamar blue assay after treatment with increasing concentration of NFV for 48 h. As demonstrated in Fig. 1D, NFV inhibited thyroid cancer cell growth in a dose- and a time-dependent manner.

To demonstrate the effects of NFV on cell cycle progression, we performed flow cytometry analysis and the results are presented in Table 1 and in Supplementary Fig. 1 (see section on supplementary data given at the end of this article). In all examined cell lines, NFV increased the proportion of cells in G0/G1 phase with the reduction of cells in S phase of the cell cycle. The most prominent effects were observed in BCPAP cells.

Table 1  FACS analysis of thyroid cancer cell lines treated with Nelfinavir.

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>G0/G1</th>
<th>S</th>
<th>G2/M</th>
</tr>
</thead>
<tbody>
<tr>
<td>133 control</td>
<td>45.1</td>
<td>37.9</td>
<td>17.0</td>
</tr>
<tr>
<td>133 NFV 10 µM</td>
<td>45.0</td>
<td>37.7</td>
<td>17.3</td>
</tr>
<tr>
<td>133 NFV 20 µM</td>
<td>61.9</td>
<td>22.1</td>
<td>16.0</td>
</tr>
<tr>
<td>BCPAP control</td>
<td>47.3</td>
<td>36.9</td>
<td>15.8</td>
</tr>
<tr>
<td>BCPAP NFV 10 µM</td>
<td>67.1</td>
<td>23.0</td>
<td>9.9</td>
</tr>
<tr>
<td>BCPAP NFV 20 µM</td>
<td>77.7</td>
<td>12.1</td>
<td>10.2</td>
</tr>
<tr>
<td>SW1736 control</td>
<td>56.0</td>
<td>31.9</td>
<td>12.1</td>
</tr>
<tr>
<td>SW1736 NFV 10 µM</td>
<td>55.9</td>
<td>31.9</td>
<td>12.2</td>
</tr>
<tr>
<td>SW1736 NFV 20 µM</td>
<td>67.8</td>
<td>21.7</td>
<td>10.5</td>
</tr>
</tbody>
</table>

Nelfinavir inhibits the expression of cell cycle regulators, induces DNA damage and apoptosis

Real-time microscopy suggested that the reduction of cell number after treatment with NFV could be the result of either cell cycle arrest or cell death. To address this question, we performed Western blot analysis with antibodies directed against cell cycle regulators (cyclin D1, CDK4 and Rb). In thyroid cancer cells, NFV decreased the expression of Cyclin D1 and CDK4 in a dose-dependent manner (Fig. 2A). The level of total Rb was significantly higher in

Figure 2

Nelfinavir affects regulators of cell cycle, DNA damage and apoptosis in thyroid cancer cells. (A) Western blot demonstrates that protein levels of Cyclin D1, CDK4 and phospho-Rb are decreased after treatment with NFV for 24 h. Total Rb protein level is unchanged after treatment with NFV (10 µM), but decreased after exposure to NFV at a concentration of 20 µM. (B) Western blot demonstrates accumulation of γH2AX protein after treatment with NFV for 24 h. (C) p53BP1 is present in foci localized in the nuclei of NFV-treated cells. (D) Dose-dependent effect upon expression of cleaved caspase 3. In BCPAP and SW1736 cells, cleavage of caspase 3 is evident after 24 h of treatment with NFV 10 µM. In FTC133 cells, NFV 10 µM did not induce cleavage of caspase 3, but treatment with NFV 20 µM did.
SW1736 cells as compared to FTC133 and BCPAP cells at baseline conditions. The highest level of phospho-Rb was detected in BCPAP cells. Nelfinavir (10 µM) decreased the level of phospho-Rb without effects on total Rb in BCPAP cells. However, in BCPAP cells as wells as in FTC133 and SW1736 cells, the protein level of total Rb was decreased after exposure to NFV at concentration 20 µM.

Treatment with NFV induced DNA damage in FTC133, BCPAP and SW1736 cells. As demonstrated in Fig. 2B, the level of γH2AX expression was increased in NFV-treated thyroid cancer cell lines in a dose-dependent manner. Immunostaining with anti-p53BP1 demonstrated the presence of foci localized in the nuclei of NFV-treated cells, but not control cells (Fig. 2C).

PTC-derived (BCPAP) cells were more sensitive to NFV-inducible apoptosis as compared to FTC-derived cells (FTC133 cells) or ATC-derived cells (SW1736 cells). As demonstrated in Fig. 2D, treatment with NFV 10 µM resulted in caspase 3 and PARP cleavage in BCPAP cells, but not in FTC133 or SW1736 cells. Induction of apoptosis was noted in all examined thyroid cancer cell lines after exposure to NFV at a concentration of 20 µM.

These results showed that at concentrations achievable clinically in patients, NFV affected the expression of genes controlling thyroid cancer cell growth and induce DNA damage.

The effects of Nelfinavir on AKT and ERK signaling in thyroid cancer cells

Growth inhibitory effects of NFV in various cancer cell lines were attributed to its ability to block HSP90 function and promote degradation of HSP90 client proteins. Because HSP90 is a binding partner for protein kinase B (AKT) and contributes to activation of ERK, we examined the effects of NFV on these signaling proteins in thyroid cancer cells. NFV decreased the levels of total AKT with concomitant decline of AKT phosphorylation in FTC133 cells. NFV had no effects on the expression of total ERK and did not inhibit ERK phosphorylation in BCPAP and SW1736 cells (Fig. 3A).

We examined the effects of NFV on expression of the BRAF V600 mutant in BCPAP and SW1736 cells. Western blot analysis with anti-BRAF V600E showed its expression in BCPAP and SW1736 but not in FTC133 cells (Fig. 3B). Treatment with NFV at concentrations of 10 µM and 20 µM was not associated with downregulation of the BRAF V600E mutant in BCPAP and SW1736 cells.

These data suggest that cytotoxic effects of NFV on thyroid cancer cells were not mediated via inhibition of the thyroid oncogene-inducible signaling pathways.

The effect of NFV on expression of thyroid-specific genes and markers of epithelial-to-mesenchymal transition

To determine if NFV influences thyroid cancer cell differentiation, we examined the expression of thyroid-specific genes by RT-PCR. Treatment with increasing concentrations of NFV did not induce changes in mRNA levels of NKX2-1, SLC5A5 and TG. We also examined the expression of molecules controlling epithelial-to-mesenchymal transition, which is critical for thyroid cancer cell migration and invasion. Expression of Twist, N-Cadherin and Vimentin mRNA was not affected by NFV. Results of RT-PCR analysis were confirmed by Western blot with specific antibodies against Vimentin and N-Cadherin (Fig. 4A).
We also examined the invasive ability of thyroid cancer cells by performing Boyden chamber migration assays. At baseline conditions, thyroid cancer cells were able to migrate through 8 µm pore membrane; at 24 h after plating onto the top chamber, more than 50% of cells migrated and were detected at the bottom surface of the membrane (Fig. 4B). In contrast, thyroid cancer cells that were treated with NFV for 24 h were not able to adhere to the top surface of the membrane; subsequently, there were no cells located at the bottom surface of the membrane.

We also examined the effects of NFV on thyroid cancer cell resistance to anoikis (a form of apoptosis that is induced by loss of cell attachment to the extracellular matrix). As demonstrated in Fig. 4C, NFV prevented the formation of spheroid-like structures in non-adherent conditions. NFV-inducible loss of cell-to-cell contacts between thyroid cancer cells growing in non-adherent conditions was associated with loss of mitochondrial membrane potential and massive cell death.

We previously reported that Connexin-43-mediated activation of gap-junctional transport, which is important for thyroid cancer cell survival in non-adherent conditions. Therefore, we examined the effects of NFV on the expression of Connexin-43 in adherent and non-adherent thyroid cancer cell lines. Treatment with NFV (10 µM) had minimal effects on Connexin-43 protein level in adherent thyroid cancer cells (Fig. 4D). Thyroid cancer cell adaptation to non-adherent conditions was associated with overexpression of Connexin-43. However, induction of Connexin-43 was significantly attenuated in cells that were treated with NFV (Fig. 4D). In non-adherent conditions, NFV decreased the protein level of Connexin-43 by 32%, 76% and 29%, respectively, in FTC133, BCPAP and SW1736 cells.

These results suggest that despite the negligible effects of NFV on the expression of mesenchymal markers, the invasive ability of thyroid cancer cells as well as their resistance to anoikis were significantly inhibited by NFV.

Discussion
The identification of new anti-cancer activities from existing, well-tolerated and effective medications represents an effective way to accelerate the translation of experimental findings into clinical application. In the present study, we examined the potential utility of NFV, a drug with well-known and tolerable side effects, for the treatment of thyroid cancer. We focused on the molecular mechanisms implicated in thyroid cancer cell response to NFV and we report several novel findings. First, we showed that NFV is toxic for thyroid cancer cells. Second, we demonstrated that the anti-cancer effects of NFV were associated with the inhibition of cell proliferation and
induction of DNA damage in thyroid cancer cells. Third, we provided evidence that NFV inhibited migratory abilities and sensitized thyroid cancer cells to anoikis.

Success in repositioning NFV for the treatment of thyroid cancer patients will rely on the ability to induce cancer cell death with a clinically achievable dose of NFV. Individual NFV plasma concentrations have been found to be highly variable in HIV-infected persons. Pharmacokinetic studies in HIV patients using NFV (1250 mg twice-daily) reported trough plasma concentration ranging from 0.36 to 10.57 mg/L (0.5–18.6 µM); the geometric mean was 1.98 mg/L or 3.5 µM (Pai & Nahata 1999, Marzolini et al. 2001). In a more recent study in 39 patients being treated for pancreatic cancer with standard NFV dosing of 1250 mg BID, trough concentrations were much less varied, ranging from 0.9 mg/L to 1.7 mg/L (1.6–3 µM); and peak concentrations ranged from 4.4 mg/L to 11.3 mg/L (7.7–20 µM) (Kattel et al. 2015).

In this study, we examined the effects of various concentrations of NFV (1–20 µM) on thyroid cancer cells growth in vitro. We employed real-time microscopy for analysis of thyroid cancer cell response to the treatment with NFV. To our knowledge, this is the first report demonstrating real-time behavior of thyroid cancer cells treated with NFV in vitro. We found that growth of examined thyroid cancer cells was significantly affected by NFV in a time-dependent manner.

In all examined thyroid cancer cell lines, we observed the prominent effects of NFV on cell division with morphological changes suggesting an aberrant transition through the S phase of the cell cycle. These observations were confirmed by flow cytometry. By performing Western blot analysis, we demonstrated that NFV (10 µM) inhibited the expression of genes controlling cell proliferation and induced DNA damage. Thyroid cancer cell exposure to NFV (20 µM) induced apoptosis.

Our findings are consistent with previous reports demonstrating growth inhibitory and pro-apoptotic effects of NFV in breast, prostate and lung cancer cell lines (Gills et al. 2007, Shim et al. 2012). Similarly to results of our study, NFV induced cell cycle arrest via inhibition of cyclin-dependent kinase and concomitant dephosphorylation of retinoblastoma tumor suppressor in melanoma cell lines (Jiang et al. 2007). Our results in BCPAP cells are consistent with findings in melanoma cell lines demonstrating that initial Rb dephosphorylation followed by decrease in total Rb protein expression during extended exposure to NFV (Jiang et al. 2007).

It has been shown that NFV acts as an inhibitor of heat shock protein 90 (HSP90) signaling and induces degradation of HSP90 client proteins (da Rocha Dias et al. 2005, Whitesell & Lindquist 2005); this activity depends on cancer cell oncogene mutation status (Shim et al. 2012). As PI3K, AKT and BRAF are substrates for the HSP90-mediated protein folding process, we examined the effects of NFV on activation of PI3K/AKT and MAPK/ERK signaling pathways in PTEN-deficient FTC133 and BRAF-positive BCPAP and SW1736 cells.

Analysis of NFV-mediated effects on activation of signaling pathways in thyroid cancer cells showed that the NFV-inducible blockade of proliferation in BCPAP and SW1736 cells was not associated with changes in p-AKT. Growth inhibitory effects of NFV were less prominent in FTC133 cells; however, in this cell line, NFV inhibited total AKT and decreased AKT phosphorylation. Our observations are consistent with previously reported findings demonstrating that AKT-dependent and AKT-independent mechanisms are involved in cancer cell response to treatment with NFV. It has been demonstrated that inhibition of AKT signaling is a major antitumor mechanism of NFV in HER2-positive, but not in HER2-negative breast cancer cells (Shim et al. 2012). In the same study, the author presented data indicating that inhibition of tumor growth under treatment with NFV occurred without significant changes in p-AKT, suggesting that mechanisms independent of AKT could play a role in the anti-cancer activities of NFV.

In our study, NFV did not decrease the protein level of the BRAF V600 mutant and did not inhibit activation of ERK in BCPAP cells. Previous work has shown that NFV may not inhibit p-ERK, but can profoundly sensitize BRAF- and NRAS-mutant melanoma cells to MAPK pathway inhibitors (Smith et al. 2016). We are currently examining the efficacy of treatment with NFV in combination with clinically available inhibitors of the MAPK pathway in thyroid cancer cells.

NFV exhibits a wide spectrum of anti-cancer activities, such as induction of endoplasmic reticulum stress, autophagy (Bruning et al. 2009), induction of oxidative stress and ROS production (Ben-Romano et al. 2006). In addition, inhibition of mitochondrial membrane potential and a decrease in intracellular ATP concentration was demonstrated in cells treated with HIV protease inhibitors (Bociaga-Jasik et al. 2013). It is possible that differential effects of NFV on BCPAP, SW1736 and FTC133 cells were observed because of different basal metabolic activity in these examined cells. In our current research,
we are exploring the role of metabolic determinants in the thyroid cancer cell response to NFV.

Previously reported studies demonstrated that NFV increased the efficacy of radiotherapy via reduction of hypoxia and improved vascularization (Gupta et al. 2005). To determine the potential use of NFV as a re-differentiating agent, we examined the expression of genes controlling RAI uptake in thyroid cells. RT-PCR showed that NFV had no significant effect on expression of thyroid-specific genes, suggesting that NFV may have a limited utility in combination with radio-iodine treatment. We must also consider that the results of in vitro experiments do not always correlate with the tumor cell response to treatment in vivo. It is still possible that NFV-inducible changes in the tumor microenvironment could potentiate the efficacy of radiotherapy, and additional studies using animal model are needed to clarify this question.

Thyroid cancers are characterized by early metastatic spread, and epithelial-to-mesenchymal transition has been demonstrated in an animal model of thyroid cancer as well as in human thyroid cancers (Vasko et al. 2007, Knauf et al. 2011). NFV did not affect expression of markers of epithelial-to-mesenchymal transition; however, it did significantly decrease the migratory ability of thyroid cancer cells. We also performed anoikis experiments and showed that NFV inhibits thyroid cancer cell survival under non-adherent conditions. As resistance to anoikis is a major factor underlying the development of metastases, our data suggest that NFV could be effective as a suppressor of metastatic dissemination.

In summary, our findings provide evidence that NFV inhibits proliferation and induces DNA damage in thyroid cancer cells. NFV also inhibits thyroid cancer cell migration and sensitizes them to anoikis. On the basis of these findings, we propose that NFV, a commonly used and well-tolerated anti-HIV drug, has a potential to become a new thyroid cancer therapeutic agent.

### References


Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA & Fagin JA 2011 Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 30:3153–3162. (doi:10.1038/onc.2011.44)


